These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. Mok S; Roycroft E; Flanagan PR; Montgomery L; Borroni E; Rogers TR; Fitzgibbon MM Antimicrob Agents Chemother; 2021 Jul; 65(8):e0261720. PubMed ID: 33972244 [TBL] [Abstract][Full Text] [Related]
29. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. Sekiguchi J; Nakamura T; Miyoshi-Akiyama T; Kirikae F; Kobayashi I; Augustynowicz-Kopec E; Zwolska Z; Morita K; Suetake T; Yoshida H; Kato S; Mori T; Kirikae T J Clin Microbiol; 2007 Sep; 45(9):2802-7. PubMed ID: 17596354 [TBL] [Abstract][Full Text] [Related]
30. Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan. Huang HT; Lin WH; Chan TH; Jou R J Microbiol Immunol Infect; 2023 Dec; 56(6):1236-1244. PubMed ID: 37690869 [TBL] [Abstract][Full Text] [Related]
31. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. Che Y; Bo D; Lin X; Chen T; He T; Lin Y BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989 [TBL] [Abstract][Full Text] [Related]
32. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. Park SK; Lee JY; Chang CL; Lee MK; Son HC; Kim CM; Jang HJ; Park HK; Jeong SH BMC Infect Dis; 2001; 1():4. PubMed ID: 11429043 [TBL] [Abstract][Full Text] [Related]
33. Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. Iwamoto T; Murase Y; Yoshida S; Aono A; Kuroda M; Sekizuka T; Yamashita A; Kato K; Takii T; Arikawa K; Kato S; Mitarai S PLoS One; 2019; 14(2):e0212798. PubMed ID: 30817803 [TBL] [Abstract][Full Text] [Related]
34. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Huang TS; Lee SS; Tu HZ; Huang WK; Chen YS; Huang CK; Wann SR; Lin HH; Liu YC Antimicrob Agents Chemother; 2003 Nov; 47(11):3672-3. PubMed ID: 14576145 [TBL] [Abstract][Full Text] [Related]
35. Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis. Huang CK; Yu MC; Hung CS; Lin JC Int J Antimicrob Agents; 2024 Apr; 63(4):107053. PubMed ID: 38081550 [TBL] [Abstract][Full Text] [Related]
36. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Zhang S; Chen J; Shi W; Liu W; Zhang W; Zhang Y Emerg Microbes Infect; 2013 Jun; 2(6):e34. PubMed ID: 26038471 [TBL] [Abstract][Full Text] [Related]